Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia

DOI: 10.1080/2162402X.2016.1211220

Keywords: CLL, CD19, immunoligand, NK cells, NKG2D, triplebody, ULBP2

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text